News & Updates
Filter by Specialty:
How does IV edaravone fare for ALS in the real world?
Intravenous (IV) edaravone seems to continue to provide hope for individuals with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease with no known cure, according to data presented at AAN 2022.
How does IV edaravone fare for ALS in the real world?
10 May 2022
Trabectedin–durvalumab combo shows antitumour activity in refractory ovarian carcinoma
Combination treatment with trabectedin and durvalumab appears to be promising in the treatment of patients with platinum-refractory ovarian carcinoma, shrinking tumour while having a manageable side effect profile, according to data from the phase Ib TRAMUNE trial.
Trabectedin–durvalumab combo shows antitumour activity in refractory ovarian carcinoma
10 May 2022
BNT162b2 prevents children from getting very sick but does not make them super immune
In the period of COVID-19 pandemic predominated by the milder yet highly transmissible Omicron variant, BNT162b2 vaccination of young children can shield them against severe infection. However, the antiviral armour afforded by this vaccine weakens over time, as reported in a recent study.
